10,877 Amgen Inc. $AMGN Shares Sold by Russell Investments Group Ltd.

Russell Investments Group Ltd. trimmed its position in Amgen Inc. (NASDAQ:AMGN – Free Report) by 3.4% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 305,174 shares of the medical research company’s stock after selling 10,877 shares during the period. Russell Investments Group Ltd. owned 0.06% of Amgen worth $128,744,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in AMGN. State Street Corp grew its stake in Amgen by 38.2% in the 2nd quarter. State Street Corp now owns 42,205,243 shares of the medical research company’s stock worth $15,283,363,000 after buying an additional 11,656,755 shares in the last quarter. MW Advisory LLC bought a new position in shares of Amgen in the 2nd quarter worth $1,054,000. Baird Financial Group Inc. increased its holdings in shares of Amgen by 1.6% in the 2nd quarter. Baird Financial Group Inc. now owns 339,825 shares of the medical research company’s stock worth $123,057,000 after buying an additional 5,496 shares during the last quarter. MassMutual Private Wealth & Trust FSB raised its position in shares of Amgen by 105.8% during the 3rd quarter. MassMutual Private Wealth & Trust FSB now owns 13,514 shares of the medical research company’s stock valued at $5,696,000 after buying an additional 6,947 shares in the last quarter. Finally, Nilsine Partners LLC purchased a new stake in shares of Amgen during the 2nd quarter valued at $3,329,000. 76.50% of the stock is currently owned by hedge funds and other institutional investors.

Amgen Stock Performance

NASDAQ AMGN opened at $465.67 on Monday. The company has a 50-day simple moving average of $425.31 and a two-hundred day simple moving average of $381.17. The company has a quick ratio of 1.20, a current ratio of 1.48 and a debt-to-equity ratio of 3.60. Amgen Inc. has a 12-month low of $312.39 and a 12-month high of $483.99. The firm has a market cap of $251.89 billion, a price-to-earnings ratio of 27.01, a PEG ratio of 3.24 and a beta of 0.43.

Amgen (NASDAQ:AMGN – Get Free Report) last announced its quarterly earnings data on Tuesday, November 3rd. The medical research company reported $6.45 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.79 by $0.66. Amgen had a return on equity of 114.99% and a net margin of 24.14%. The firm had revenue of $10.37 billion for the quarter, compared to analysts’ expectations of $10.07 billion. During the same period last year, the firm earned $5.64 earnings per share. The company’s revenue for the quarter was up 8.5% compared to the same quarter last year. On average, equities analysts forecast that Amgen Inc. will post 23.37 EPS for the current year.

Amgen Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, December 11th. Investors of record on Friday, November 20th will be given a dividend of $2.52 per share. This represents a $10.08 annualized dividend and a yield of 2.2%. The ex-dividend date is Friday, November 20th. Amgen’s dividend payout ratio (DPR) is presently 58.47%.

Wall Street Analysts Forecast Growth

AMGN has been the subject of a number of research analyst reports. Morgan Stanley lifted their price objective on shares of Amgen from $359.00 to $410.00 and gave the stock an “equal weight” rating in a report on Wednesday, November 4th. Leerink Partners increased their target price on Amgen from $395.00 to $464.00 and gave the company a “market perform” rating in a research note on Thursday, November 5th. Mizuho raised their price target on Amgen from $303.00 to $352.00 and gave the company a “neutral” rating in a research report on Tuesday, August 18th. Wall Street Zen raised Amgen from a “hold” rating to a “buy” rating in a research note on Sunday, October 18th. Finally, Robert W. Baird increased their price objective on Amgen from $215.00 to $230.00 and gave the company an “underperform” rating in a research report on Wednesday, August 5th. One analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, eighteen have issued a Hold rating and three have assigned a Sell rating to the stock. According to MarketBeat.com, Amgen has a consensus rating of “Hold” and an average price target of $424.66.

Read Our Latest Stock Report on Amgen

About Amgen

(Free Report)

Amgen is a biotechnology company that discovers, develops, manufactures and commercializes medicines for serious illnesses. Its research and product portfolio span areas including cancer, cardiovascular disease, inflammation, bone health and rare diseases. The company’s medicines include Enbrel, Prolia, Xgeva and Repatha. Amgen serves patients and healthcare providers in the United States and markets its products internationally. Founded in 1980 and headquartered in Thousand Oaks, California, Amgen is led by Robert A. Bradway, who has served as its chief executive officer since 2012.

Read More

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.